



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

April 2023





© 2023 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to people living with HIV throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

April 2023

N = 7566



Health Authority	Male	Female	All
FRASER	1529	473	2002
INTERIOR	453	118	571
NORTHERN	146	77	223
VANCOUVER COASTAL	3301	444	3745
VANCOUVER ISLAND	823	168	991
	6252	1280	7532
		Unknown/not stated:	34
		Total:	7566

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (April 2018 - April 2023)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (April 2018 - April 2023)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (April 2018 - April 2023)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (April 2018 - April 2023)






1.6 Percent Distribution of Active Participants by CD4 Count
(April 2018 - April 2023)






1.7 Percent Distribution of Inactive Participants by CD4 Count (April 2018 - April 2023)






1.8 Active and Inactive Participants (April 2018 - April 2023)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (April 2018 - April 2023)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT
(April 2018 - April 2023)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(April 2018 - April 2023)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (April 2018 - April 2023)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(April 2018 - April 2023)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (April 2018 - April 2023)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (April 2018 - April 2023)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(April 2018 - April 2023)






1.18 Baseline CD4 for Antiretroviral First Starts (April 2018 - April 2023)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (April 2018 - April 2023)






1.20 Cumulative Resistance Testing Results by Resistance Category (April 2018 - April 2023)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (April 2018 - April 2023)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2023
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	31	4	0	4	1	1030	4	<40	4
1988	32	4	0	4	1	450	4	<40	3
1989	30	50	1	51	25	520	48	<40	3
1990	28	52	1	53	29	510	51	<40	3
1991	29	35	3	38	13	550	35	<40	3
1992	29	53	5	58	23	580	56	<40	3
1993	28	114	15	129	70	580	123	<40	3
1994	26	66	11	77	47	530	75	<40	3
1995	26	120	20	140	67	590	124	<40	3
1996	24	303	48	351	181	570	318	<40	3
1997	22	258	32	290	161	560	262	<40	3
1998	22	176	38	214	130	595	193	<40	3
1999	21	148	37	185	116	600	170	<40	3
2000	22	113	25	138	78	565	120	<40	3
2001	21	109	26	135	75	590	123	<40	3
2002	20	117	24	141	78	580	129	<40	3
2003	20	132	26	158	97	553	147	<40	3
2004	18	140	35	175	109	630	160	<40	3
2005	17	173	43	216	131	640	190	<40	3
2006	16	163	39	202	119	630	178	<40	3
2007	16	226	44	270	170	655	252	<40	3
2008	15	267	60	327	212	645	291	<40	3
2009	14	295	60	355	222	650	324	<40	3
2010	12	248	67	315	196	660	284	<40	3
2011	12	311	64	375	228	700	334	<40	3
2012	11	260	66	326	190	720	294	<40	3
2013	10	250	66	316	198	670	288	<40	3
2014	9	261	49	310	172	715	273	<40	3
2015	8	260	44	304	173	670	270	<40	3
2016	7	237	53	290	170	700	254	<40	3
2017	6	198	31	229	146	690	208	<40	3
2018	5	177	50	227	134	710	201	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2023
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	4	220	41	261	172	700	237	<40	3
2020	3	174	54	228	156	740	197	<40	3
2021	2	182	33	215	135	660	197	<40	3
2022	1	269	51	320	223	670	294	<40	3
2023	0	98	20	118	106	530	116	<40	3
Total:		6263	1282	7545					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	7465	756	1878	<40	1317	650
FEB-2022	7386	774	1803	<40	1263	620
MAR-2022	7458	766	1904	<40	1251	620
APR-2022	7420	778	1755	<40	1153	620
MAY-2022	7477	763	1998	<40	1305	620
JUN-2022	7482	759	1839	<40	1200	630
JUL-2022	7495	754	1761	<40	1139	645
AUG-2022	7493	758	1990	<40	1227	620
SEP-2022	7443	771	1787	<40	1091	640
OCT-2022	7469	777	1849	<40	1163	640
NOV-2022	7502	783	1898	<40	1198	630
DEC-2022	7544	787	1607	<40	1003	640
JAN-2023	7583	793	2051	<40	1306	650
FEB-2023	7525	807	1727	<40	1003	630
MAR-2023	7560	803	1978	<40	1186	640
APR-2023	7566	796	1763	<40	1055	630

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	786	273	55	<40	45	580
FEB-2022	856	232	73	<40	56	635
MAR-2022	800	285	94	<40	73	480
APR-2022	834	278	70	<40	53	550
MAY-2022	775	334	60	<40	43	490
JUN-2022	778	317	61	<40	43	400
JUL-2022	781	297	61	<50	35	453
AUG-2022	803	275	59	78	49	560
SEP-2022	860	223	71	<40	53	460
OCT-2022	843	230	83	<40	61	500
NOV-2022	830	236	80	50	60	505
DEC-2022	795	258	57	<40	45	560
JAN-2023	754	319	63	<40	45	550
FEB-2023	806	248	66	<40	53	550
MAR-2023	766	268	74	<40	52	510
APR-2023	769	271	64	<40	42	590

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2022	7432	786	19	7	161	144	2	14503
FEB-2022	7371	856	8	9	151	211	-61	14528
MAR-2022	7432	800	16	9	232	160	61	14557
APR-2022	7397	834	11	1	156	178	-35	14577
MAY-2022	7450	775	13	13	205	146	53	14601
JUN-2022	7457	778	11	15	178	170	7	14638
JUL-2022	7469	781	10	13	188	176	12	14677
AUG-2022	7469	803	15	17	169	171	0	14715
SEP-2022	7424	860	13	15	146	191	-45	14743
OCT-2022	7445	843	14	16	196	171	21	14778
NOV-2022	7481	830	9	17	209	177	36	14817
DEC-2022	7512	795	19	8	213	167	31	14844
JAN-2023	7553	754	20	10	194	143	41	14879
FEB-2023	7509	806	10	11	159	204	-44	14903
MAR-2023	7545	766	15	21	199	169	36	14937
APR-2023	7545	769	13	13	172	166	0	14965

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2022	499	6468	455	43	7465	6.68%	86.64%	6.10%	0.58%	100.00%
FEB-2022	525	6371	445	45	7386	7.11%	86.26%	6.02%	0.61%	100.00%
MAR-2022	550	6408	455	45	7458	7.37%	85.92%	6.10%	0.60%	100.00%
APR-2022	567	6357	450	46	7420	7.64%	85.67%	6.06%	0.62%	100.00%
MAY-2022	597	6381	452	47	7477	7.98%	85.34%	6.05%	0.63%	100.00%
JUN-2022	614	6376	450	42	7482	8.21%	85.22%	6.01%	0.56%	100.00%
JUL-2022	634	6371	445	45	7495	8.46%	85.00%	5.94%	0.60%	100.00%
AUG-2022	643	6366	441	43	7493	8.58%	84.96%	5.89%	0.57%	100.00%
SEP-2022	663	6296	439	45	7443	8.91%	84.59%	5.90%	0.60%	100.00%
OCT-2022	679	6310	439	41	7469	9.09%	84.48%	5.88%	0.55%	100.00%
NOV-2022	696	6318	446	42	7502	9.28%	84.22%	5.95%	0.56%	100.00%
DEC-2022	709	6344	449	42	7544	9.40%	84.09%	5.95%	0.56%	100.00%
JAN-2023	721	6373	445	44	7583	9.51%	84.04%	5.87%	0.58%	100.00%
FEB-2023	735	6322	429	39	7525	9.77%	84.01%	5.70%	0.52%	100.00%
MAR-2023	750	6324	445	41	7560	9.92%	83.65%	5.89%	0.54%	100.00%
APR-2023	765	6319	441	41	7566	10.11%	83.52%	5.83%	0.54%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	3 20%	3064 42%	3 20%	2480 34%	0 0%	19 0%	12 80%	2922 40%	0 0%	1473 20%	12 80%	4262 58%
FEB-2022	6 24%	3019 42%	3 12%	2410 33%	2 8%	19 0%	15 60%	2939 41%	4 16%	1395 19%	19 76%	4225 58%
MAR-2022	3 10%	3034 41%	2 7%	2406 33%	0 0%	19 0%	24 83%	3029 41%	2 7%	1350 18%	26 90%	4272 58%
APR-2022	4 20%	3019 41%	3 15%	2366 33%	0 0%	19 0%	14 70%	3052 42%	2 10%	1313 18%	16 80%	4250 58%
MAY-2022	4 17%	3026 41%	3 13%	2354 32%	0 0%	18 0%	17 74%	3145 43%	2 9%	1282 17%	19 83%	4309 59%
JUN-2022	5 14%	3015 41%	0 0%	2309 31%	0 0%	19 0%	29 81%	3199 44%	4 11%	1237 17%	31 86%	4320 59%
JUL-2022	4 10%	3007 41%	3 8%	2285 31%	0 0%	19 0%	27 69%	3229 44%	9 23%	1218 17%	35 90%	4343 59%
AUG-2022	5 14%	2992 41%	4 11%	2262 31%	0 0%	18 0%	29 78%	3271 45%	3 8%	1178 16%	32 86%	4353 59%
SEP-2022	4 14%	2953 40%	3 11%	2196 30%	0 0%	17 0%	19 68%	3284 45%	5 18%	1173 16%	24 86%	4352 60%
OCT-2022	6 17%	2951 40%	4 11%	2174 30%	0 0%	16 0%	29 83%	3350 46%	0 0%	1143 16%	29 83%	4388 60%
NOV-2022	7 18%	2948 40%	5 13%	2158 29%	0 0%	15 0%	26 68%	3387 46%	6 16%	1136 15%	31 82%	4417 60%
DEC-2022	4 15%	2951 40%	3 11%	2148 29%	1 4%	16 0%	18 67%	3446 47%	5 19%	1109 15%	23 85%	4445 60%
JAN-2023	6 17%	2972 40%	1 3%	2148 29%	1 3%	16 0%	23 66%	3491 47%	8 23%	1096 15%	29 83%	4466 60%
FEB-2023	3 13%	2945 40%	1 4%	2098 28%	0 0%	17 0%	18 75%	3504 47%	3 13%	1067 14%	21 88%	4449 60%
MAR-2023	2 6%	2939 40%	2 6%	2074 28%	0 0%	15 0%	27 79%	3557 48%	5 15%	1055 14%	32 94%	4486 60%
APR-2023	3 11%	2951 40%	1 4%	2070 28%	0 0%	15 0%	23 82%	3557 48%	3 11%	1033 14%	25 89%	4479 60%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	0 0%	1 0%	0 0%	476 29%	0 0%	1132 68%	0 0%	60 4%	0 0%	1 0%	0 0%	1 0%
FEB-2022	0 0%	1 0%	1 33%	447 28%	1 33%	1110 69%	1 33%	60 4%	0 0%	1 0%	0 0%	1 0%
MAR-2022	0 0%	1 0%	0 0%	430 27%	2 100%	1113 70%	0 0%	57 4%	0 0%	1 0%	0 0%	1 0%
APR-2022	0 0%	1 0%	0 0%	424 27%	0 0%	1085 69%	0 0%	56 4%	0 0%	1 0%	0 0%	1 0%
MAY-2022	0 0%	1 0%	1 33%	417 27%	2 67%	1080 70%	0 0%	53 3%	0 0%	1 0%	0 0%	1 0%
JUN-2022	0 0%	1 0%	0 0%	407 27%	1 100%	1056 70%	0 0%	52 3%	0 0%	1 0%	0 0%	1 0%
JUL-2022	0 0%	1 0%	0 0%	405 27%	1 100%	1039 70%	0 0%	50 3%	0 0%	1 0%	0 0%	1 0%
AUG-2022	0 0%	1 0%	0 0%	386 26%	1 100%	1028 70%	0 0%	45 3%	0 0%	1 0%	0 0%	1 0%
SEP-2022	0 0%	0 0%	0 0%	368 26%	2 100%	1010 71%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
OCT-2022	0 0%	0 0%	0 0%	355 25%	0 0%	1002 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
NOV-2022	0 0%	0 0%	0 0%	352 25%	6 100%	995 72%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
DEC-2022	0 0%	0 0%	0 0%	341 24%	1 100%	1008 72%	0 0%	45 3%	0 0%	1 0%	0 0%	1 0%
JAN-2023	0 0%	0 0%	0 0%	339 25%	1 100%	994 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
FEB-2023	0 0%	0 0%	0 0%	321 24%	0 0%	955 73%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
MAR-2023	0 0%	0 0%	0 0%	317 24%	1 100%	954 73%	0 0%	42 3%	0 0%	1 0%	0 0%	1 0%
APR-2023	0 0%	0 0%	0 0%	305 23%	1 100%	960 74%	0 0%	42 3%	0 0%	1 0%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	0 0%	103 9%	0 0%	328 30%	0 0%	130 12%	0 0%	317 29%	0 0%	235 21%
FEB-2022	0 0%	106 10%	0 0%	317 29%	0 0%	127 12%	0 0%	306 28%	1 100%	228 21%
MAR-2022	0 0%	113 11%	1 100%	303 28%	0 0%	132 12%	0 0%	301 28%	0 0%	222 21%
APR-2022	1 50%	124 12%	1 50%	301 28%	0 0%	130 12%	0 0%	297 28%	0 0%	223 21%
MAY-2022	0 0%	136 13%	0 0%	287 27%	0 0%	128 12%	0 0%	290 27%	1 100%	220 21%
JUN-2022	1 33%	149 14%	1 33%	284 27%	0 0%	122 12%	0 0%	285 27%	1 33%	211 20%
JUL-2022	0 0%	155 15%	1 33%	280 27%	0 0%	117 11%	0 0%	280 27%	2 67%	207 20%
AUG-2022	0 0%	157 15%	1 33%	275 27%	0 0%	119 12%	0 0%	274 27%	2 67%	204 20%
SEP-2022	0 0%	167 16%	3 100%	271 27%	0 0%	110 11%	0 0%	273 27%	0 0%	200 20%
OCT-2022	0 0%	173 17%	0 0%	261 26%	0 0%	105 10%	0 0%	269 27%	0 0%	196 20%
NOV-2022	1 33%	183 18%	2 67%	261 26%	0 0%	108 11%	0 0%	269 26%	0 0%	197 19%
DEC-2022	0 0%	186 19%	1 25%	254 25%	0 0%	107 11%	1 25%	262 26%	2 50%	195 19%
JAN-2023	3 43%	192 19%	4 57%	247 25%	0 0%	107 11%	0 0%	255 26%	0 0%	191 19%
FEB-2023	0 0%	202 20%	0 0%	250 25%	0 0%	98 10%	0 0%	249 25%	0 0%	190 19%
MAR-2023	0 0%	209 21%	0 0%	243 25%	0 0%	101 10%	0 0%	246 25%	0 0%	186 19%
APR-2023	1 50%	215 22%	1 50%	232 24%	0 0%	96 10%	0 0%	245 25%	0 0%	187 19%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		fostemsavir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	11 73%	2421 43%	2 13%	2468 44%	1 7%	347 6%	0 0%	0 0%	0 0%	24 0%	1 7%	374 7%
FEB-2022	15 71%	2443 44%	6 29%	2437 44%	0 0%	331 6%	0 0%	0 0%	0 0%	21 0%	0 0%	369 7%
MAR-2022	23 85%	2536 45%	3 11%	2460 43%	1 4%	324 6%	0 0%	0 0%	0 0%	21 0%	0 0%	370 7%
APR-2022	14 74%	2574 45%	5 26%	2436 43%	0 0%	312 5%	0 0%	0 0%	0 0%	20 0%	0 0%	366 6%
MAY-2022	17 77%	2666 46%	5 23%	2455 43%	0 0%	309 5%	0 0%	0 0%	0 0%	22 0%	0 0%	360 6%
JUN-2022	29 85%	2710 47%	5 15%	2454 42%	0 0%	300 5%	0 0%	0 0%	0 0%	22 0%	0 0%	352 6%
JUL-2022	24 69%	2745 47%	7 20%	2452 42%	3 9%	297 5%	0 0%	0 0%	0 0%	22 0%	1 3%	342 6%
AUG-2022	26 76%	2790 48%	6 18%	2452 42%	1 3%	294 5%	0 0%	0 0%	1 3%	22 0%	1 3%	340 6%
SEP-2022	19 76%	2820 48%	6 24%	2433 42%	0 0%	281 5%	0 0%	0 0%	0 0%	21 0%	0 0%	323 6%
OCT-2022	28 80%	2889 49%	6 17%	2440 41%	1 3%	280 5%	0 0%	0 0%	0 0%	22 0%	0 0%	314 5%
NOV-2022	24 73%	2920 49%	8 24%	2462 41%	1 3%	276 5%	0 0%	1 0%	0 0%	22 0%	0 0%	309 5%
DEC-2022	16 70%	2974 50%	5 22%	2465 41%	1 4%	270 4%	0 0%	1 0%	0 0%	20 0%	1 4%	307 5%
JAN-2023	23 82%	3016 50%	5 18%	2493 41%	0 0%	269 4%	0 0%	1 0%	0 0%	21 0%	0 0%	302 5%
FEB-2023	18 75%	3042 50%	6 25%	2477 41%	0 0%	255 4%	0 0%	1 0%	0 0%	21 0%	0 0%	288 5%
MAR-2023	25 74%	3090 51%	5 15%	2485 41%	2 6%	260 4%	0 0%	1 0%	0 0%	20 0%	2 6%	291 5%
APR-2023	21 81%	3091 51%	4 15%	2499 41%	1 4%	259 4%	0 0%	1 0%	0 0%	18 0%	0 0%	275 4%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		3 drugs from 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2022	985	13.19	773	10.35	4452	59.64	496	6.64	673	9.02	86	1.15
FEB-2022	958	12.97	750	10.15	4409	59.69	522	7.07	667	9.03	80	1.08
MAR-2022	934	12.52	737	9.88	4482	60.10	548	7.35	673	9.02	84	1.13
APR-2022	908	12.24	725	9.77	4473	60.28	565	7.61	669	9.02	80	1.08
MAY-2022	898	12.01	709	9.48	4527	60.55	595	7.96	668	8.93	80	1.07
JUN-2022	873	11.67	705	9.42	4558	60.92	612	8.18	658	8.79	76	1.02
JUL-2022	857	11.43	698	9.31	4578	61.08	632	8.43	654	8.73	76	1.01
AUG-2022	829	11.06	691	9.22	4610	61.52	641	8.55	648	8.65	74	0.99
SEP-2022	800	10.75	691	9.28	4575	61.47	662	8.89	641	8.61	74	0.99
OCT-2022	789	10.56	673	9.01	4620	61.86	678	9.08	636	8.52	73	0.98
NOV-2022	770	10.26	682	9.09	4639	61.84	694	9.25	645	8.60	72	0.96
DEC-2022	773	10.25	663	8.79	4681	62.05	706	9.36	650	8.62	71	0.94
JAN-2023	751	9.90	665	8.77	4729	62.36	718	9.47	648	8.55	72	0.95
FEB-2023	716	9.51	665	8.84	4715	62.66	733	9.74	625	8.31	71	0.94
MAR-2023	701	9.27	654	8.65	4744	62.75	748	9.89	643	8.51	70	0.93
APR-2023	707	9.34	653	8.63	4745	62.71	762	10.07	634	8.38	65	0.86

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2022	7	1	0	1	1	3	490
FEB-2022	9	0	1	0	1	5	530
MAR-2022	9	4	1	1	1	2	150
APR-2022	1	0	0	0	0	1	820
MAY-2022	13	4	1	1	1	6	490
JUN-2022	15	1	4	1	4	4	400
JUL-2022	13	1	4	3	2	2	225
AUG-2022	17	1	3	3	2	5	330
SEP-2022	15	1	0	3	6	4	405
OCT-2022	16	0	0	1	5	9	520
NOV-2022	17	1	2	2	5	6	445
DEC-2022	8	1	1	2	0	1	320
JAN-2023	10	2	2	2	2	2	285
FEB-2023	11	2	2	3	1	3	253
MAR-2023	21	0	0	4	3	11	530
APR-2023	13	1	3	1	2	5	400

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2022	12307	3763
FEB-2022	12331	3778
MAR-2022	12360	3794
APR-2022	12389	3819
MAY-2022	12380	3808
JUN-2022	12395	3810
JUL-2022	12421	3819
AUG-2022	12442	3831
SEP-2022	12461	3840
OCT-2022	12488	3861
NOV-2022	12495	3850
DEC-2022	12472	3832
JAN-2023	12465	3819
FEB-2023	12453	3804
MAR-2023	12461	3804
APR-2023	12439	3773

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved


Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7566
Apr-2023

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Apr-2023

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Apr-2023

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Apr-2023

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Apr-2023

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Apr-2023

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	0
	35-49	*	*	6
	50+	*	*	18
	Total HSDA:	45	61	24
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	72	100	51	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	433	590	323	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	231	311	173	
Total HA:		781	1062	571

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		781	1062	571

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	160	218	118
Male	621	844	453

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	571	57	660	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	26	*
	5 years or more	12	*
	<5 years	7	*
	Total HSDA:	45	24
KOOTENAY BOUNDARY	10 years or more	47	29
	5 years or more	12	10
	<5 years	13	12
	Total HSDA:	72	51
OKANAGAN	10 years or more	276	204
	5 years or more	87	64
	<5 years	70	55
	Total HSDA:	433	323
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	143	112
	5 years or more	44	28
	<5 years	44	33
	Total HSDA:	231	173
Total HA:		781	571

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	492	359
5 years or more	155	108
<5 years	134	104
Total HA:	781	571

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	52	70	11	17
KOOTENAY BOUNDARY	79	138	24	45
OKANAGAN	238	1076	53	341
THOMPSON/CARIBOO/SHUSWAP	150	564	36	144
Total:	519	1848	124	547

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	9
KOOTENAY BOUNDARY	12
OKANAGAN	65
THOMPSON/CARIBOO/SHUSWAP	46
Total:	132

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	6
	20-34	36	38	28
	35-49	101	106	70
	50+	263	364	200
	Total HSDA:	407	515	304
FRASER NORTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1150	1554	868
FRASER SOUTH	0-19	9	9	9
	20-34	104	106	80
	35-49	301	329	234
	50+	627	955	507
	Total HSDA:	1041	1399	830
Total HA:		2598	3468	2002

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	17	17	16
	20-34	277	282	205
	35-49	762	820	575
	50+	1542	2349	1206
Total HA:		2598	3468	2002

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	633	808	473
Male	1965	2660	1529

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	2002	53	660	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	270	208
	5 years or more	68	40
	<5 years	69	56
	Total HSDA:	407	304
FRASER NORTH	10 years or more	719	515
	5 years or more	235	188
	<5 years	196	165
	Total HSDA:	1150	868
FRASER SOUTH	10 years or more	647	503
	5 years or more	214	170
	<5 years	180	157
	Total HSDA:	1041	830
Total HA:		2598	2002

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1636	1226
	5 years or more	517	398
	<5 years	445	378
Total HA:		2598	2002

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	148	536	34	64
FRASER NORTH	259	1615	39	220
FRASER SOUTH	227	1797	47	497
Total:	634	3948	120	781

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	201
FRASER NORTH	720
FRASER SOUTH	474
Total:	1395

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		351	522
RICHMOND	20-34	31	32	18
	35-49	53	54	43
	50+	121	177	103
	Total HSDA:	205	263	164
VANCOUVER	0-19	12	12	9
	20-34	447	462	306
	35-49	1218	1356	864
	50+	2983	5318	2127
	Total HSDA:	4660	7148	3306
Total HA:		5216	7933	3745

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	13	13	10
	20-34	507	523	343
	35-49	1345	1492	961
	50+	3351	5905	2431
Total HA:		5216	7933	3745

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	596	963	444
Male	4618	6968	3301
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3745	55	660	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	236	186
	5 years or more	58	45
	<5 years	57	44
	Total HSDA:	351	275
RICHMOND	10 years or more	127	99
	5 years or more	33	25
	<5 years	45	40
	Total HSDA:	205	164
VANCOUVER	10 years or more	3234	2227
	5 years or more	823	594
	<5 years	603	485
	Total HSDA:	4660	3306
Total HA:		5216	3745

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	3597	2512
5 years or more	914	664
<5 years	705	569
Total HA:	5216	3745

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	186	418	39	57
RICHMOND	45	313	9	95
VANCOUVER	683	11686	213	5430
Total:	914	12417	261	5582

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	72

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		357	522
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		128	180
SOUTH VANCOUVER ISLAND	20-34	69	75	48
	35-49	192	218	146
	50+	543	863	414
	Total HSDA:	804	1156	608
Total HA:		1289	1858	991

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		1289	1858	991

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	219	319	168
Male	1070	1539	823

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	991	56	600	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	216	173
	5 years or more	77	52
	<5 years	64	55
	Total HSDA:	357	280
NORTH VANCOUVER ISLAND	10 years or more	89	73
	5 years or more	25	19
	<5 years	14	11
	Total HSDA:	128	103
SOUTH VANCOUVER ISLAND	10 years or more	496	358
	5 years or more	163	131
	<5 years	145	119
	Total HSDA:	804	608
Total HA:		1289	991

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	801	604
	5 years or more	265	202
	<5 years	223	185
Total HA:		1289	991

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	203	928	72	162
NORTH VANCOUVER ISLAND	160	283	40	71
SOUTH VANCOUVER ISLAND	223	1940	36	586
Total:	586	3151	148	819

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	108
NORTH VANCOUVER ISLAND	44
SOUTH VANCOUVER ISLAND	126
Total:	278

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	8	8	*
	35-49	17	20	*
	50+	28	36	*
	Total HSDA:	53	64	30
NORTH WEST	20-34	*	6	0
	35-49	*	37	17
	50+	*	77	37
	Total HSDA:	72	120	54
NORTHERN INTERIOR	0-19	6	6	*
	20-34	19	19	*
	35-49	57	73	*
	50+	113	196	*
	Total HSDA:	195	294	139
Total HA:		320	478	223

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	31	33	*
	35-49	97	130	*
	50+	186	309	*
Total HA:		320	478	223

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	115	176	77
Male	205	302	146

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	223	53	570	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	31	*
	5 years or more	6	*
	<5 years	16	*
	Total HSDA:	53	30
NORTH WEST	10 years or more	52	39
	5 years or more	10	8
	<5 years	10	7
	Total HSDA:	72	54
NORTHERN INTERIOR	10 years or more	103	75
	5 years or more	60	41
	<5 years	32	23
	Total HSDA:	195	139
Total HA:		320	223

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	186	128
	5 years or more	76	52
	<5 years	58	43
Total HA:		320	223

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	39	60	6	8
NORTH WEST	86	176	14	35
NORTHERN INTERIOR	124	502	23	194
Total:	249	738	43	237

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	5
NORTH WEST	19
NORTHERN INTERIOR	12
Total:	36

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	5	11	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	31	51	*
	THOMPSON/CARIBOO/SHUSWAP	25	50	*
	Total HA:	67	121	48
FRASER	FRASER EAST	36	51	30
	FRASER NORTH	48	91	38
	FRASER SOUTH	84	121	62
	Total HA:	168	263	130
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	52	24
	RICHMOND	6	11	5
	VANCOUVER	451	903	365
	Total HA:	482	966	394
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	46	81	36
	NORTH VANCOUVER ISLAND	16	30	11
	SOUTH VANCOUVER ISLAND	50	97	38
	Total HA:	112	208	85
NORTHERN	NORTH EAST	10	14	*
	NORTH WEST	31	67	*
	NORTHERN INTERIOR	68	115	*
	Total HA:	109	196	81
Total:		938	1754	738

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	344	629	276
Male	594	1125	462

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	738	53	540	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Antiretroviral: a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla: the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Descovy: the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.





Monthly Report

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir: an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine: a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fostemsavir: an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.





Monthly Report

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.





Monthly Report

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

